favipiravir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 4887 259793-96-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • favipiravir
  • avigan
  • T-705
A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase. Several studies reported the use of favipiravir for the treatment of COVID-19 but additional data are needed to substantiate the initial reports. Given the lack of pharmacokinetic and safety data for the high favipiravir dosages proposed for treatment of COVID-19, the drug should be used with caution at such dosages.
  • Molecular weight: 157.10
  • Formula: C5H4FN3O2
  • CLOGP: 1.02
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 89.10
  • ALOGS: -1.26
  • ROTB: 1

Drug dosage:

DoseUnitRoute
1.60 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 24, 2014 PMDA Toyama Chemical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 357.15 120.47 127 228 556053 55735659

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 841.34 88.03 304 507 346970 31349563
Intentional product use issue 93.48 88.03 38 773 49309 31647224

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 1169.85 86.68 431 815 742629 70184569
COVID-19 144.72 86.68 58 1188 105699 70821499
COVID-19 pneumonia 101.34 86.68 30 1216 21939 70905259

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AX27 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Other antivirals
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:149553 anticoronaviral drug
CHEBI has role CHEBI:170010 EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Influenza caused by pandemic influenza virus indication 719865001
Coronavirus infection off-label use 186747009
Pregnancy, function contraindication 289908002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.57 acidic
pKa2 11.39 acidic
pKa3 1.24 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
EW5GL2X7E0 UNII
D09537 KEGG_DRUG
C1138226 UMLSCUI
CHEBI:134722 CHEBI
CHEMBL221722 ChEMBL_ID
492405 PUBCHEM_CID
DB12466 DRUGBANK_ID
8916 INN_ID
C462182 MESH_SUPPLEMENTAL_RECORD_UI
11139 IUPHAR_LIGAND_ID
018626 NDDF
1163580005 SNOMEDCT_US
1172871009 SNOMEDCT_US

Pharmaceutical products:

None